Inpharma 1500 - 13 Aug 2005

Long-term Adderall XR demandsattention in paediatric ADHD

Long-term SLI 381 [Adderall XR] is "persistentlyeffective" and well tolerated in children with attention-deficit hyperactivity disorder (ADHD), according toresearchers from the US.

Their multicentre, open-label, extension studyinvolved 568 patients aged 6–12 years who received oralSLI 381 10 mg/day for 24 months; dosages could beincreased to a maximum of 30 mg/day to achieveoptimal efficacy.*

An analysis of scores on the Conners Global IndexScale, Parent version (CGIS-P) showed a significant,continued improvement. Mean CGIS-P scores improvedby > 30% within the first 3 months of treatment inpatients who had experienced treatment interruptionbetween studies; this improvement was maintainedthroughout the remaining study period and wassignificant at each quarter, relative to baseline. CGIS-Pscore improvements were also maintained in patientswhose active treatment had been continuous.

Adverse events (AEs) were reported in 92% of the totalstudy population; 15% of patients withdrew from thestudy because of AEs. However, most AEs were eithermild (63%) or moderate (34%).* This study was funded by Shire Pharmaceutical Development, US.

McGough JJ, et al. Long-term tolerability and effectiveness of once-daily mixedamphetamine salts (Adderall XR) in children with ADHD. Journal of the AmericanAcademy of Child and Adolescent Psychiatry 44: 530-538, No. 6, Jun2005 801012821

1

Inpharma 13 Aug 2005 No. 15001173-8324/10/1500-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved